Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer: An Eastern Cooperative Oncology Group study

P. Bonomi, D. Finkelstein, A. Chang

Research output: Contribution to journalArticlepeer-review

Abstract

Identification of effective new chemotherapeutic agents is a major objective of clinical research efforts in patients who have metastatic non- small cell lung cancer (NSCLC). Canadian investigators observed responses in NSCLC when acivicin was given as a daily IV bolus for 5 consecutive days. Based on these results the Eastern Cooperative Oncology Group tested acivicin as a continuous infusion in patients with advanced NSCLC. A total of 82 patients were entered on a Phase II trial in which patients have randomized either to acivicin 60 mg/m2 given as a continuous intravenous infusion over 72 hours repeated every 28 days or to the reference regimen which consisted of cisplatin 60 mg/m2 intravenously on day 1 and etoposide 120 mg/m2 daily on days 1, 2, and 3 repeated every 28 days. Five partial remissions (11%) were observed in 42 patients treated with etoposide-cisplatin, and no responses were observed in 40 patients treated with acivicin. Median survival durations for etoposide cisplatin and for acivicin were 29.7 and 21.1 weeks, respectively. Based on these results, acivicin appears to be inactive in NSCLC.

Original languageEnglish (US)
Pages (from-to)215-217
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume17
Issue number3
DOIs
StatePublished - 1994
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer: An Eastern Cooperative Oncology Group study'. Together they form a unique fingerprint.

Cite this